1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
申请人:Mercep Mladen
公开号:US20050148577A1
公开(公告)日:2005-07-07
The present invention relates to 1-oxa-dibenzoazulene derivatives, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-α (TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
1-oxa-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
申请人:Mercep Mladen
公开号:US20050209214A1
公开(公告)日:2005-09-22
The present invention relates to 1-oxa-dibenzoazulene derivatives, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-α (TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
USE OF 1-OXADIBENZO E,H AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
申请人:PLIVA-ISTRAZIVACKI INSTITUT d.o.o.
公开号:EP1684742A1
公开(公告)日:2006-08-02
USE OF 1-OXADIBENZO [E,H] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
申请人:GlaxoSmithKline istrazivacki centar Zagreb d.o.o.
公开号:EP1684742B1
公开(公告)日:2009-01-14
1-Oxadibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders
申请人:Mercep Mladen
公开号:US20070173493A1
公开(公告)日:2007-07-26
The present invention relates to the use of compounds from the group of 1-oxadibenzo[e,h]azulenes and of their pharmacologically acceptable salts and solvates in pharmaceutical formulation for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium of biogenic amines or other neurotransmitters.